Debate: Should immunotherapy be used in RPL? Paternal leukocyte immunization - for

Recurrent Pregnancy Loss: Causes, Controversies and Treatment

Volumn , Issue , 2007, Pages 179-184

  Clark, David A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349106276     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (31)

1. Clark DA. Shall we properly re-examine the status of allogeneic therapy for recurrent early pregnancy failure? Am J Reprod Immunol 2004; 51:7–15.
2. Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32:55–72.
3. Collins JA, Roberts RM. Reports of independent analyses of data from the worldwide prospective collaborative study on immunotherapy for recurrent unexplained abortion: Immunotherapy for recurrent spontaneous abortion:Analysis l.Am J Reprod Immunol 1994;32:275–80.
4. Scott JR. Immunotherapy for recurrent spontaneous abortion: Analysis 2. Am J Reprod Immunol 1994; 32:279–80.
5. Clark DA, Coulam CB, Daya S, et al. Unexplained sporadic and recurrent miscarriage in the new millennium: A critical analysis of immune mechanisms and treatment. Hum Reprod Update 2001; 7:501–11.
6. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006; (2):CD000112.
7. Christiansen OB, Nybo Andersen AM, Bosch E, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 2005; 83:821–39.
8. Vamvakas EC, Blajchman MA, eds. Immunomodulatory Effects of Blood Transfusion. Bethesda, MD: AAAB Press, 1999.
9. Illeni MT, Marelli G, Parazzini F, et al. Immunotherapy and recurrent abortion: a randomized clinical trial. Hum Reprod 1994; 9:1247–9.
10. Mowbray JF. Immunology of early pregnancy. Hum Reprod 1988; 3:79–82.
11. Mowbray JF, Underwood JL. Effect of paternal lymphocyte immunization on birthweight and pregnancy outcome. In: Chaouat G, Mowbray JF, eds. Cellular and Molecular Biology of the Materno-Fetal Relationship. Paris: INSERM/John Libby Eurotext, Colloque 212,1991:295–302.
12. Clark DA, Daya S. Trials and tribulations in the treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1991; 25:18–24.
13. Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immunization in prevention of recurrent miscarriages: a randomized trial. Lancet 1999; 354:365–9.
14. Pandey MJ, Agrawal S. Induction of MLR-Bf and protection of fetal loss: a current double blind randomized trial of paternal lymphocyte immunization for women with recurrent spontaneous abortion. Int Immunopharmacol 2004; 4:289–98.
15. Daya S, Gunby J, and the Recurrent Miscarriage Immunotherapy Trialists Group. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32:294–303.
16. Clark DA, Daya S, Coulam CB, et al. Implications of abnormal human trophoblast karyotype of the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35:495–8.
17. Carp HJA. Immunization with refrigerated paternal cells did not prevent recurrent miscarriage. Evidence Based Obstet Gynecol 2000; 2:49.
18. Clark DA, Chaouat G. Loss of surface CD200 on stored allogeneic leukocytes may impair anti-abortive effect in vivo. Am J Reprod Immunol 2004; 53:13–20.
19. Unander M. In: Beard RW, Sharp, F eds. Early Pregnancy Loss: Mechanisms and Treatment. London: RCOG/Ashton-under-Lyne, UK: Peacock Press, 1988: 400–3.
20. Clark DA, Banwatt D. Altered expression of cell surface CD200 tolerance- signaling molecule on human PBL stored at 4°C or 37°C correlates with reduced or increased efficacy in controlled trials of treatment of recurrent spontaneous abortion. Am J Reprod Immunol 2006; 55:392–3.
21. Clark DA, Gunby J, Daya S. The use of allogeneic leukocytes or IVIg G for the treatment of patients with recurrent spontaneous abortion. Transfus Med Rev 1997; 11:65–94.
22. Benson K, Hartz AJ. A comparison of observational studies and randomized controlled trials. N Engl J Med 2000; 342:1878–86.
23. Kling C, Steinmann J, Westphal E, et al. Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum Reprod 2006; 21:429–35.
24. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo 29. transfer (IVF). J Assist Reprod Genet 2006; 23:1–13.
25. Aoki K, Kajijura S, Matsumoto Y, et al. Preconceptional natural-killer-cell actIVIty as a predictor of miscarriage. Lancet 1995;345:1340–2. 30.
26. Shakhar K, Rosenne E, Lowenthan R, et al. High NK cell actIVIty in recurrent miscarriage: what are we really measuring? Hum Reprod 2006; 21:2421–5.
27. Tsuda H, Sakai M, Michimata T, et al. Characterization of NKT cells in human peripheral blood and decidual lymphocytes. Am J Reprod Immunol 2001; 45:295–302.
28. Sasaki Y, Sasaki M, Miyazaki S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004; 10:347–53.
29. Kitade H, Kawai M, Rutgeerts O, et al. Early presence of regulatory cells in transplanted rats rendered tolerant by donor-specific blood transfusion. J Immunol 2005; 175:4963–70.
30. Scarpellini F, Grasso JA, Sbracia M, et al. GM-CSF treatment of women with habitual abortion showing low expression of IL-10 in secretory endometria. Am J Reprod Immunol 2005; 53:307–8.
31. Clark DA, Fernandes J, Banwatt D. Prevention of abortion in the CBA xDBA/2 model by intravaginal TGF-P is associated with local recruitment of predominantly CD8+ FOXp3+ T cells to the genital tract. Am J Reprod Immunol 2006; 55:392.